{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:16:42Z","timestamp":1788031002463,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2019_Kolleg_14"],"award-info":[{"award-number":["2019_Kolleg_14"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Meningioma is the most common primary brain tumour in adults. However, molecular drivers of progression occurring in a subset of meningiomas are poorly understood. We hypothesise that epigenomic variations are causal for the clinical heterogeneity of meningiomas and may be functionally relevant for disease progression. To test this hypothesis, we perform global DNA methylation profiling of a large cross-sectional cohort and a longitudinal cohort of human meningiomas. Our analysis identifies a DNA hypermethylation signature that is correlated with clinical outcomes and enables more accurate prognostication for meningiomas than previous classification systems. Analyses of longitudinal high-grade meningioma samples in comparison to clinically benign meningiomas and normal meningeal tissue show convergent contributions but differing plasticity of copy number variations and DNA hypermethylation along the trajectory of meningioma progression. Systematic analysis of DNA hypermethylation in high-grade meningiomas unravels a tumour suppressive role of clustered protocadherins by restricting \u03b2-catenin nuclear localisation, consistent with the association between nuclear \u03b2-catenin staining and meningioma progression. Together, our study provides fundamental insights into the molecular mechanisms underlying the heterogeneity of clinically benign and aggressive meningiomas and the microevolutionary adaptation during disease progression.<\/jats:p>","DOI":"10.1038\/s41467-026-77170-3","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:54:56Z","timestamp":1788029696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-6919","authenticated-orcid":false,"given":"Daniel J.","family":"Merk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4917-273X","authenticated-orcid":false,"given":"Peter","family":"Pa\u00dflack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender","family":"Surender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Tsiami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-4280","authenticated-orcid":false,"given":"Lara A.","family":"Haeusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2389-0215","authenticated-orcid":false,"given":"Vanessa","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayasarathy","family":"Sampath-Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-6273","authenticated-orcid":false,"given":"Lisa","family":"Sevenich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5930-0636","authenticated-orcid":false,"given":"Andrea D.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiit","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"G\u00f6tt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Tellermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Behling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6209","authenticated-orcid":false,"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"77170_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 25, iv1\u2013iv99 (2023).","journal-title":"Neuro Oncol."},{"key":"77170_CR2","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/onc.2010.609","volume":"30","author":"M Kalamarides","year":"2011","unstructured":"Kalamarides, M. et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30, 2333\u20132344 (2011).","journal-title":"Oncogene"},{"key":"77170_CR3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner, R. et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 23, 1821\u20131834 (2021).","journal-title":"Neuro Oncol."},{"key":"77170_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/neuonc\/noab243","volume":"24","author":"M Preusser","year":"2022","unstructured":"Preusser, M. et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 24, 755\u2013767 (2022).","journal-title":"Neuro Oncol."},{"key":"77170_CR5","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","volume":"51","author":"NL Albert","year":"2024","unstructured":"Albert, N. L. et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur. J. Nucl. Med Mol. Imaging 51, 3662\u20133679 (2024).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"77170_CR6","doi-asserted-by":"crossref","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23,(2021).","DOI":"10.1093\/neuonc\/noab106"},{"key":"77170_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","volume":"8","author":"EA Williams","year":"2020","unstructured":"Williams, E. A. et al. Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol. Commun. 8, 171 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"77170_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos, P. K. et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45, 285\u2013289 (2013).","journal-title":"Nat. Genet."},{"key":"77170_CR9","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark, V. E. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077\u20131080 (2013).","journal-title":"Science"},{"key":"77170_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","volume":"2","author":"WL Bi","year":"2017","unstructured":"Bi, W. L. et al. Genomic landscape of high-grade meningiomas. NPJ Genom. Med. 2, 15 (2017).","journal-title":"NPJ Genom. Med."},{"key":"77170_CR11","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang, J. Z. et al. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 26, 1742\u20131780 (2024).","journal-title":"Neuro Oncol."},{"key":"77170_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","volume":"27","author":"F Sahm","year":"2025","unstructured":"Sahm, F. et al. cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 27, 319\u2013330 (2025).","journal-title":"Neuro Oncol."},{"key":"77170_CR13","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2016","unstructured":"Sahm, F. et al. TERT promoter mutations and risk of recurrence in meningioma. J. Natl. Cancer Inst. 108, djv377 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"77170_CR14","doi-asserted-by":"publisher","first-page":"109228","DOI":"10.18632\/oncotarget.22650","volume":"8","author":"TA Juratli","year":"2017","unstructured":"Juratli, T. A. et al. Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas. Oncotarget 8, 109228\u2013109237 (2017).","journal-title":"Oncotarget"},{"key":"77170_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1023\/A:1013863630293","volume":"55","author":"M Simon","year":"2001","unstructured":"Simon, M. et al. Alterations of INK4a(p16-p14ARF)\/INK4b(p15) expression and telomerase activation in meningioma progression. J. Neurooncol. 55, 149\u2013158 (2001).","journal-title":"J. Neurooncol."},{"key":"77170_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","volume":"140","author":"P Sievers","year":"2020","unstructured":"Sievers, P. et al. CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 140, 409\u2013413 (2020).","journal-title":"Acta Neuropathol."},{"key":"77170_CR17","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/neuonc\/noaf105","volume":"27","author":"P Sievers","year":"2025","unstructured":"Sievers, P. et al. Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Neuro Oncol. 27, 2326\u20132340 (2025).","journal-title":"Neuro Oncol."},{"key":"77170_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682\u2013694 (2017).","journal-title":"Lancet Oncol."},{"key":"77170_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"77170_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649\u2013659 (2022).","journal-title":"Nat. Genet."},{"key":"77170_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/neuonc\/noac224","volume":"25","author":"A Choudhury","year":"2023","unstructured":"Choudhury, A. et al. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 25, 520\u2013530 (2023).","journal-title":"Neuro Oncol."},{"key":"77170_CR22","doi-asserted-by":"publisher","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","volume":"8","author":"JCT Bayley","year":"2022","unstructured":"Bayley, J. C. T. et al. Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci. Adv. 8, eabm6247 (2022).","journal-title":"Sci. Adv."},{"key":"77170_CR23","first-page":"e123","volume":"46","author":"W Zhou","year":"2018","unstructured":"Zhou, W., Triche, T. J. Jr, Laird, P. W. & Shen, H. SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions. Nucleic Acids Res. 46, e123 (2018).","journal-title":"Nucleic Acids Res."},{"key":"77170_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"77170_CR25","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","volume":"39","author":"SLN Maas","year":"2021","unstructured":"Maas, S. L. N. et al. Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated. J. Clin. Oncol. 39, 3839\u20133852 (2021).","journal-title":"J. Clin. Oncol."},{"key":"77170_CR26","doi-asserted-by":"publisher","first-page":"btae029","DOI":"10.1093\/bioinformatics\/btae029","volume":"40","author":"B Daenekas","year":"2024","unstructured":"Daenekas, B. et al. Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice. Bioinformatics 40, btae029 (2024).","journal-title":"Bioinformatics"},{"key":"77170_CR27","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1038\/s41591-024-03167-4","volume":"30","author":"JZ Wang","year":"2024","unstructured":"Wang, J. Z. et al. Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma. Nat. Med. 30, 3173\u20133183 (2024).","journal-title":"Nat. Med."},{"key":"77170_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18582-7","volume":"11","author":"ST Magill","year":"2020","unstructured":"Magill, S. T. et al. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat. Commun. 11, 4803 (2020).","journal-title":"Nat. Commun."},{"key":"77170_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696\u2013705 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"77170_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/jnen\/nlad036","volume":"82","author":"AD Maier","year":"2023","unstructured":"Maier, A. D. et al. DNA methylation profile of human dura and leptomeninges. J. Neuropathol. Exp. Neurol. 82, 641\u2013649 (2023).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"77170_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4772-0","volume":"19","author":"K Street","year":"2018","unstructured":"Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genom. 19, 477 (2018).","journal-title":"BMC Genom."},{"key":"77170_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0695-0","volume":"11","author":"AF Vega-Benedetti","year":"2019","unstructured":"Vega-Benedetti, A. F. et al. Clustered protocadherins methylation alterations in cancer. Clin. Epigenet. 11, 100 (2019).","journal-title":"Clin. Epigenet."},{"key":"77170_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1074\/mcp.M900343-MCP200","volume":"9","author":"MH Han","year":"2010","unstructured":"Han, M. H., Lin, C., Meng, S. & Wang, X. Proteomics analysis reveals overlapping functions of clustered protocadherins. Mol. Cell Proteom. 9, 71\u201383 (2010).","journal-title":"Mol. Cell Proteom."},{"key":"77170_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep31665","volume":"6","author":"KM Mah","year":"2016","unstructured":"Mah, K. M., Houston, D. W. & Weiner, J. A. The gamma-Protocadherin-C3 isoform inhibits canonical Wnt signalling by binding to and stabilizing Axin1 at the membrane. Sci. Rep. 6, 31665 (2016).","journal-title":"Sci. Rep."},{"key":"77170_CR35","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1016\/j.celrep.2018.03.013","volume":"22","author":"HN Vasudevan","year":"2018","unstructured":"Vasudevan, H. N. et al. Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Rep. 22, 3672\u20133683 (2018).","journal-title":"Cell Rep."},{"key":"77170_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/neuonc\/noq081","volume":"12","author":"E Perez-Magan","year":"2010","unstructured":"Perez-Magan, E. et al. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol. 12, 1278\u20131290 (2010).","journal-title":"Neuro Oncol."},{"key":"77170_CR37","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1038\/onc.2011.609","volume":"31","author":"AR Dallosso","year":"2012","unstructured":"Dallosso, A. R. et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene 31, 4409\u20134419 (2012).","journal-title":"Oncogene"},{"key":"77170_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00441-007-0512-5","volume":"331","author":"K Akat","year":"2008","unstructured":"Akat, K., Bleck, C. K., Lee, Y. M., Haselmann-Weiss, U. & Kartenbeck, J. Characterization of a novel type of adherens junction in meningiomas and the derived cell line HBL-52. Cell Tissue Res. 331, 401\u2013412 (2008).","journal-title":"Cell Tissue Res."},{"key":"77170_CR39","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/labinvest.3700307","volume":"85","author":"S Puttmann","year":"2005","unstructured":"Puttmann, S. et al. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Investig. 85, 1163\u20131171 (2005).","journal-title":"Lab Investig."},{"key":"77170_CR40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/cancers11040545","volume":"11","author":"G Jungwirth","year":"2019","unstructured":"Jungwirth, G. et al. Identification of KIF11 as a novel target in meningioma. Cancers 11, 545 (2019).","journal-title":"Cancers"},{"key":"77170_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","volume":"27","author":"WH Lee","year":"1990","unstructured":"Lee, W. H. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 27, 389\u2013395 (1990).","journal-title":"Neurosurgery"},{"key":"77170_CR42","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S","volume":"64","author":"K Tanaka","year":"1989","unstructured":"Tanaka, K. et al. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 64, 2243\u20132249 (1989).","journal-title":"Cancer"},{"key":"77170_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1101\/gr.119867.110","volume":"22","author":"AF Fernandez","year":"2012","unstructured":"Fernandez, A. F. et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 22, 407\u2013419 (2012).","journal-title":"Genome Res."},{"key":"77170_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature13268","volume":"510","author":"V Hovestadt","year":"2014","unstructured":"Hovestadt, V. et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510, 537\u2013541 (2014).","journal-title":"Nature"},{"key":"77170_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00401-012-1077-2","volume":"125","author":"EC Schwalbe","year":"2013","unstructured":"Schwalbe, E. C. et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 125, 359\u2013371 (2013).","journal-title":"Acta Neuropathol."},{"key":"77170_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41588-025-02475-w","volume":"58","author":"SLN Maas","year":"2026","unstructured":"Maas, S. L. N. et al. A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification. Nat. Genet. 58, 341\u2013354 (2026).","journal-title":"Nat. Genet."},{"key":"77170_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-024-01739-6","volume":"12","author":"F Ehret","year":"2024","unstructured":"Ehret, F. et al. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas. Acta Neuropathol. Commun. 12, 74 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"77170_CR48","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41588-024-01747-1","volume":"56","author":"CG Lucas","year":"2024","unstructured":"Lucas, C. G. et al. Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution. Nat. Genet. 56, 1121\u20131133 (2024).","journal-title":"Nat. Genet."},{"key":"77170_CR49","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar, G. M. & Santagata, S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 19, 1447\u20131456 (2017).","journal-title":"Neuro Oncol."},{"key":"77170_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31659-0","volume":"8","author":"G Collord","year":"2018","unstructured":"Collord, G. et al. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Sci. Rep. 8, 13537 (2018).","journal-title":"Sci. Rep."},{"key":"77170_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.trsl.2012.05.007","volume":"160","author":"A Di Vinci","year":"2012","unstructured":"Di Vinci, A. et al. HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl. Res. 160, 355\u2013362 (2012).","journal-title":"Transl. Res."},{"key":"77170_CR52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/carcin\/bgr260","volume":"33","author":"Y Kishida","year":"2012","unstructured":"Kishida, Y. et al. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33, 436\u2013441 (2012).","journal-title":"Carcinogenesis"},{"key":"77170_CR53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00401-019-02008-w","volume":"138","author":"N Paramasivam","year":"2019","unstructured":"Paramasivam, N. et al. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol. 138, 295\u2013308 (2019).","journal-title":"Acta Neuropathol."},{"key":"77170_CR54","doi-asserted-by":"publisher","first-page":"e54114","DOI":"10.1371\/journal.pone.0054114","volume":"8","author":"F Gao","year":"2013","unstructured":"Gao, F. et al. DNA methylation in the malignant transformation of meningiomas. PLoS One 8, e54114 (2013).","journal-title":"PLoS One"},{"key":"77170_CR55","doi-asserted-by":"publisher","first-page":"e1000745","DOI":"10.1371\/journal.pgen.1000745","volume":"5","author":"AR Dallosso","year":"2009","unstructured":"Dallosso, A. R. et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms\u2019 tumor. PLoS Genet. 5, e1000745 (2009).","journal-title":"PLoS Genet."},{"key":"77170_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52284-8","volume":"15","author":"CD Eaton","year":"2024","unstructured":"Eaton, C. D. et al. Merlin(S13) phosphorylation regulates meningioma Wnt signaling and magnetic resonance imaging features. Nat. Commun. 15, 7873 (2024).","journal-title":"Nat. Commun."},{"key":"77170_CR57","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.3390\/cancers14246227","volume":"14","author":"S Hergalant","year":"2022","unstructured":"Hergalant, S. et al. Correlation between DNA methylation and cell proliferation identifies new candidate predictive markers in meningioma. Cancers 14, 6227 (2022).","journal-title":"Cancers"},{"key":"77170_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina, M. J. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157\u2013172 (2008).","journal-title":"Stat. Med."},{"key":"77170_CR59","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"77170_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26840-5","volume":"12","author":"M Bolis","year":"2021","unstructured":"Bolis, M. et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat. Commun. 12, 7033 (2021).","journal-title":"Nat. Commun."},{"key":"77170_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00401-024-02777-z","volume":"148","author":"SLN Maas","year":"2024","unstructured":"Maas, S. L. N. et al. Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma. Acta Neuropathol. 148, 17 (2024).","journal-title":"Acta Neuropathol."},{"key":"77170_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"77170_CR63","doi-asserted-by":"publisher","unstructured":"Merk, D. J. & Tabatabai, G. Meningioma_DNA_methylation_project. figshare https:\/\/doi.org\/10.6084\/m9.figshare.32043249 (2026).","DOI":"10.6084\/m9.figshare.32043249"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77170-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:11:59Z","timestamp":1788030719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77170-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77170"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77170-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional funding to the University Hospital T\u00fcbingen was provided as financial compensation for the following activities: G.T. has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure, Servier), as a consultant (Bayer, Boehringer Ingelheim, CureVac), as a steering committee member in non-interventional trials (Bayer, Novocure), as a speaker (Novocure, Servier). The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9236"}}